Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc Ord (OP: AZNCF )

139.30 +3.00 (+2.20%)
Streaming Delayed Price Updated: 10:00 AM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 581
Open 139.30
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 136.30
Today's Range 139.30 - 139.30
52wk Range 104.50 - 144.50
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pieris Pharma Pushes Elarekibep Data Readout, Investors React Negatively
 
Via Benzinga
AstraZeneca Axes Pneumonia Drug Pact With Aridis
AstraZeneca plc (NASDAQ: AZN) scrapped its license agreement with Aridis Pharmaceuticals Inc (NASDAQ: ARDS). 
Via Benzinga

Performance

YTD
+2.10%
+2.10%
1 Month
+2.94%
+2.94%
3 Month
+2.43%
+2.43%
6 Month
+28.67%
+28.67%
1 Year
+2.34%
+2.34%

More News

Read More
AstraZeneca-Ionis Partnered Rare Disease Drug Data Shows Sustained Benefit; Drug Under FDA Review
Via Benzinga
AstraZenceca's Tagrisso Shows Survival Benefit In Early-Stage Lung Cancer Settings
Via Benzinga
AstraZeneca's Immunotherapy Imfinzi Shows Improvement In Survival Chances In Lung Cancer Patients
Via Benzinga
Schrodinger is an AI-Powered Drug Discovery Developer to Watch
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
Via Benzinga
AstraZeneca Forecasts Growth In 2023 Earnings, Revenue Despite Fall In COVID-19 Products, Plans To Deliver 15 New Medicines This Decade
Via Benzinga
AstraZeneca's New Asthma Treatment for Adults Gets Green Light from FDA
Via Benzinga
AstraZeneca To Acquire CinCor Pharma To Strengthen Cardiorenal Pipeline
Via Benzinga
AstraZeneca's Current Valuation Not Reflective Of Its Strong Fundamentals, Analyst Says
Via Benzinga
Europe Approves AstraZeneca's Two Combo Therapies For Prostate, Bile Duct Cancer Settings
Via Benzinga
AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs
Via Benzinga
AstraZeneca Drug Imfinzi Fails As Monotherapy In Metastatic Lung Cancer Setting
Via Benzinga
FDA Extends Review Period For AstraZeneca-Merck Partnered Cancer Drug, Lynparza
Via Benzinga
AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients
Via Benzinga
AstraZeneca Highlights Detailed Data From Two Breast Cancer Trials
Via Benzinga
AstraZeneca's Enhertu Cuts Risk Of Death By 36% VsTrastuzumab In Metastatic Breast Cancer
Via Benzinga
AstraZeneca Bets On UK Listed Firm For Lung Diseases
Via Benzinga
Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says
Via Benzinga
European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs
Via Benzinga
FDA Approves AstraZeneca's Imfinzi/Imjudo Chemo Combo For Late Stage Lung Cancer
Via Benzinga
AstraZeneca Ditches US Application Submission For COVID-19 Shot, Q3 Edges Analyst Expectations On Oncology Strength
Via Benzinga
FDA Adcomm Backs AstraZeneca's 2-In-1 Asthma Inhaler, Only For Adults Being Less Sure For Adolescents, Kids
Via Benzinga
Europe Approves AstraZeneca-Sanofi Partnered Antibody To Prevent RSV Infection In Infants
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.